Back
Protagonist Therapeutics 10K Form
Buy
63
PTGX
Protagonist Therapeutics
Last Price:
32.48
Seasonality Move:
4.6%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-02 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2023-08-03 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2023-05-04 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2022-11-08 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2022-08-04 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
| 2022-05-05 | 10Q | PTGX/Protagonist Therapeutics Quarterly |
Receive PTGX News And Ratings
See the #1 stock for the next 7 days that we like better than PTGX
PTGX Financial Statistics
Sales & Book Value
| Annual Sales: | $60M |
|---|---|
| Cash Flow: | $-27.67M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $9.56 |
| Price / Book: | 3.4 |
Profitability
| EPS (TTM): | 2.44000 |
|---|---|
| Net Income (TTM): | $162.11M |
| Gross Margin: | -- |
| Return on Equity: | 47.41% |
| Return on Assets: | 43.17% |
Protagonist Therapeutics Earnings Forecast
Key Protagonist Therapeutics Financial Ratios
- The Research & Development expenses have been 200.27% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- The Net Earning history of PTGX is -131.59% of Total Revenues.
- Per Share Earnings over the last 10 years have been positive in 5 years.
Protagonist Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | PTGX |
| CUSIP: | 74366E |
| Website: | protagonist-inc.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 15.72 |
| Quick Ratio: | 15.61 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
PTGX Technical Analysis vs Fundamental Analysis
Buy
63
Protagonist Therapeutics (PTGX)
is a Buy
Is Protagonist Therapeutics a Buy or a Sell?
-
Protagonist Therapeutics stock is rated a Buy
The current Protagonist Therapeutics [PTGX] share price is $32.47. The Score for PTGX is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.